| 1 |
35362343 | Fluvoxamine used to treat COVID-19 resulting in theophylline toxicity from CYP 1A2 drug-drug interaction. | 2022 Apr 1 |
1 |
| 2 |
34564289 | Selective Serotonin Reuptake Inhibitors and Clozapine: Clinically Relevant Interactions and Considerations. | 2021 Sep 1 |
1 |
| 3 |
33302490 | A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine. | 2020 Dec 8 |
1 |
| 4 |
30762305 | Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam. | 2019 May |
1 |
| 5 |
31172535 | Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects. | 2019 Dec |
1 |
| 6 |
31182321 | Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations. | 2019 Aug |
1 |
| 7 |
29101463 | A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors. | 2018 Jan |
1 |
| 8 |
29155491 | Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors. | 2018 Apr |
2 |
| 9 |
27821711 | Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction Metabolized. | 2017 Jan |
2 |
| 10 |
26626327 | The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review. | 2016 Mar |
1 |
| 11 |
26886336 | Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance. | 2016 Mar |
1 |
| 12 |
25159194 | Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects. | 2015 Feb |
1 |
| 13 |
25719307 | Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland. | 2015 Sep |
1 |
| 14 |
26099559 | Simulation of Metabolic Drug-Drug Interactions Perpetrated by Fluvoxamine Using Hybridized Two-Compartment Hepatic Drug-Pool-Based Tube Modeling and Estimation of In Vivo Inhibition Constants. | 2015 Oct |
2 |
| 15 |
24793403 | Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. | 2014 Jun |
1 |
| 16 |
24846087 | Clozapine-associated development of second-onset obsessive compulsive symptoms in schizophrenia: impact of clozapine serum levels and fluvoxamine add-on. | 2014 May |
1 |
| 17 |
23001793 | Stereoselective interaction between tetrahydropalmatine enantiomers and CYP enzymes in human liver microsomes. | 2013 Jan |
2 |
| 18 |
21277363 | Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes. | 2011 Apr 10 |
1 |
| 19 |
21979923 | Augmentative effects of fluvoxamine on duloxetine plasma levels in depressed patients. | 2011 Nov |
2 |
| 20 |
20435083 | Cytochromes P4501 (CYP1): catalytic activities and inducibility by diesel exhaust particle extract and benzo[a]pyrene in intact human lung ex vivo. | 2010 Jun 29 |
1 |
| 21 |
19225771 | Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease. | 2009 Jul |
2 |
| 22 |
19593168 | ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. | 2009 Aug |
1 |
| 23 |
19843060 | In vitro and in vivo evaluation of the inhibition potential of risperidone toward clozapine biotransformation. | 2009 Oct |
1 |
| 24 |
18438654 | The effect of fluvoxamine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects. | 2008 Jul |
1 |
| 25 |
18690879 | Enzyme inhibition and induction in liver disease. | 2008 Jan |
1 |
| 26 |
18691982 | Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. | 2008 Jul |
1 |
| 27 |
18816299 | In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. | 2008 Aug |
1 |
| 28 |
17166674 | Re-evaluation of tacrine hepatotoxicity using gel entrapped hepatocytes. | 2007 Jan 30 |
3 |
| 29 |
17214606 | Metabolic drug interactions with newer antipsychotics: a comparative review. | 2007 Jan |
1 |
| 30 |
17504220 | CYP-mediated clozapine interactions: how predictable are they? | 2007 May |
1 |
| 31 |
17596106 | Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. | 2007 |
3 |
| 32 |
17823102 | Drug interactions with smoking. | 2007 Sep 15 |
1 |
| 33 |
16678550 | Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. | 2006 May |
4 |
| 34 |
16893613 | Co-administration of ramelton and fluvoxamine to increase levels of interleukin-2. | 2006 |
2 |
| 35 |
16918719 | Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine. | 2006 Aug |
2 |
| 36 |
16985100 | Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions. | 2006 Dec |
1 |
| 37 |
17045169 | Metabolism of the A1 adenosine receptor PET ligand [18F]CPFPX by CYP1A2: implications for bolus/infusion PET studies. | 2006 Oct |
1 |
| 38 |
15738749 | Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy. | 2005 Apr |
2 |
| 39 |
15845683 | The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. | 2005 May |
2 |
| 40 |
16236038 | Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. | 2005 Nov |
2 |
| 41 |
14749694 | Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. | 2004 Jan |
1 |
| 42 |
15060511 | Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. | 2004 Apr |
1 |
| 43 |
15199661 | Some aspects of genetic polymorphism in the biotransformation of antidepressants. | 2004 Jan-Feb |
1 |
| 44 |
15545309 | Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia. | 2004 Dec |
1 |
| 45 |
12695344 | Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. | 2003 May |
1 |
| 46 |
12828569 | In vitro metabolism of genistein and tangeretin by human and murine cytochrome P450s. | 2003 Jul |
1 |
| 47 |
14703714 | Metabolic drug interactions with new psychotropic agents. | 2003 Oct |
1 |
| 48 |
11803239 | Interaction between fluvoxamine and cotinine or caffeine. | 2002 |
1 |
| 49 |
11876575 | Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. | 2002 Feb |
1 |
| 50 |
11907488 | Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). | 2002 Mar |
5 |